<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>11 courses of <z:chebi fb="0" ids="16586">EACA</z:chebi> were given to 9 acutely ill, severely thrombocytopenic patients (platelet count less than 20 X 10(9)/l) </plain></SENT>
<SENT sid="1" pm="."><plain>6 patients were being treated for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> while 1 each had cyclical <z:hpo ids='HP_0004859'>amegakaryocytic thrombocytopenia</z:hpo>, <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e> and advanced <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>8 were refractory to HLA-matched platelets and 1 refused blood product transfusion </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had simultaneous major medical complications such as <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:hpo ids='HP_0001913'>granulocytopenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The highest dose of <z:chebi fb="0" ids="16586">EACA</z:chebi> used was 24 mg/d </plain></SENT>
<SENT sid="5" pm="."><plain>Improvement in haemostasis was noted in <z:hpo ids='HP_0000001'>all</z:hpo> patients with successful control of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> in 1, control of <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> in 3 and lack of significant <z:mp ids='MP_0001914'>bleeding</z:mp> for 4-29 d in the remaining 5 patients </plain></SENT>
<SENT sid="6" pm="."><plain>The only toxicity was dose-related <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Since this patient group was at extremely high risk for haemorrhage, we conclude that <z:chebi fb="0" ids="16586">EACA</z:chebi> is safe and useful in the management of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> including that occurring during leukaemic induction </plain></SENT>
</text></document>